glycine has been researched along with Cachexia in 8 studies
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glycine protects skeletal muscle from cancer-induced wasting and loss of function, reduces the oxidative and inflammatory burden, and reduces the expression of genes associated with muscle protein breakdown in cancer cachexia." | 7.80 | Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. ( Chee, A; Ham, DJ; Koopman, R; Lynch, GS; Murphy, KT, 2014) |
| "Glycine protects skeletal muscle from cancer-induced wasting and loss of function, reduces the oxidative and inflammatory burden, and reduces the expression of genes associated with muscle protein breakdown in cancer cachexia." | 3.80 | Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. ( Chee, A; Ham, DJ; Koopman, R; Lynch, GS; Murphy, KT, 2014) |
| " To address this problem, we have measured the synthetic rate of fibrinogen (perhaps the major acute phase protein) and plasma amino acid profiles in a group of patients with adenocarcinoma of the pancreas and an ongoing inflammatory response (serum C-reactive protein >10 mg/L in the absence of any other obvious infective or inflammatory cause)." | 3.70 | Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. ( Falconer, JS; Fearon, KC; McMillan, DC; Preston, T; Shenkin, A; Slater, C, 1998) |
| " Cumulative nitrogen retention was positive for both dosage groups (low dose, 15." | 2.67 | Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. ( Butterfield, GE; Harrison, D; Hoffman, AR; Lieberman, SA, 1994) |
| "Cancer cachexia is a complex metabolic disorder accounting for ~20% of cancer-related deaths, yet its metabolic landscape remains unexplored." | 1.91 | Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia. ( Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Matsuo, K; Mishiro-Sato, E; Muro, K; Narita, Y; Nozawa, K; Ogata, T; Oze, I; Satoh, K; Soga, T; Taketo, MM, 2023) |
| "The mechanisms underlying cancer cachexia - the proximate cause of at least 20% of cancer-related deaths - have until recently remained rather obscure." | 1.51 | Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia. ( Iloki-Assanga, S; Lujany, LML; McCarty, MF, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kojima, Y | 1 |
| Mishiro-Sato, E | 1 |
| Fujishita, T | 1 |
| Satoh, K | 1 |
| Kajino-Sakamoto, R | 1 |
| Oze, I | 1 |
| Nozawa, K | 1 |
| Narita, Y | 1 |
| Ogata, T | 1 |
| Matsuo, K | 1 |
| Muro, K | 1 |
| Taketo, MM | 1 |
| Soga, T | 1 |
| Aoki, M | 1 |
| McCarty, MF | 1 |
| Iloki-Assanga, S | 1 |
| Lujany, LML | 1 |
| Ham, DJ | 1 |
| Murphy, KT | 1 |
| Chee, A | 1 |
| Lynch, GS | 1 |
| Koopman, R | 1 |
| Muqaku, B | 1 |
| Eisinger, M | 1 |
| Meier, SM | 1 |
| Tahir, A | 1 |
| Pukrop, T | 1 |
| Haferkamp, S | 1 |
| Slany, A | 1 |
| Reichle, A | 1 |
| Gerner, C | 1 |
| Le Bricon, T | 1 |
| Cynober, L | 1 |
| Field, CJ | 1 |
| Baracos, VE | 1 |
| Lieberman, SA | 1 |
| Butterfield, GE | 1 |
| Harrison, D | 1 |
| Hoffman, AR | 1 |
| Kinscherf, R | 1 |
| Hack, V | 1 |
| Fischbach, T | 1 |
| Friedmann, B | 1 |
| Weiss, C | 1 |
| Edler, L | 1 |
| Bärtsch, P | 1 |
| Dröge, W | 1 |
| Preston, T | 1 |
| Slater, C | 1 |
| McMillan, DC | 1 |
| Falconer, JS | 1 |
| Shenkin, A | 1 |
| Fearon, KC | 1 |
2 trials available for glycine and Cachexia
| Article | Year |
|---|---|
Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anthropometry; Body Mass Index; Cachexia; Carrier Protein | 1994 |
Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine.
Topics: Acetylcysteine; Adult; Aerobiosis; Anaerobiosis; Body Weight; Cachexia; Cystine; Exercise; Female; G | 1996 |
6 other studies available for glycine and Cachexia
| Article | Year |
|---|---|
Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia.
Topics: Animals; Cachexia; Glycine; Humans; Liver; Mice; Niacin; Proteomics; Pyridoxine; Stomach Neoplasms; | 2023 |
Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia.
Topics: 3-Hydroxybutyric Acid; Adipocytes; Biotin; Cachexia; Carnitine; Catechin; Coumaric Acids; Dietary Su | 2019 |
Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Topics: Adipose Tissue; Animals; Body Mass Index; Cachexia; Cell Line, Tumor; Disease Models, Animal; Fatty | 2014 |
Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma.
Topics: Asparagine; Biomarkers, Tumor; Blood Platelets; Cachexia; Calcium; Glycine; Humans; Melanoma; Metabo | 2017 |
Supplemental nutrition with ornithine alpha-ketoglutarate in rats with cancer-associated cachexia: surgical treatment of the tumor improves efficacy of nutritional support.
Topics: Amino Acids; Animals; Body Weight; Cachexia; Combined Modality Therapy; Eating; Food, Fortified; Glu | 1995 |
Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response.
Topics: Acute-Phase Reaction; Adenocarcinoma; Adult; Aged; Amino Acids; C-Reactive Protein; Cachexia; Fastin | 1998 |